Can a new pill ease postpartum depression? a Real-World study investigates
NCT ID NCT07047820
First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time
Summary
This study follows adults in the United States who were prescribed zuranolone for postpartum depression (PPD) after giving birth. Researchers will track symptom changes using a standard questionnaire called the Edinburgh Postnatal Depression Scale (EPDS) at several time points, including 15 days after the first dose. The goal is to see whether symptoms improve in real-world settings, outside of controlled clinical trials. Participants will also report on breastfeeding, use of other medications, and their overall health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- zuranolone
- What this could lead to
- If symptoms improve, this could support zuranolone as an effective real-world treatment for postpartum depression, helping new mothers recover faster.
- What could go wrong
- This is an observational study without a control group, so it cannot prove cause and effect. Results may be influenced by other factors, and not all participants may respond to the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
305 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Aug 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants prescribed zuranolone who consent to participate in this study and meet all the inclusion criteria, none of the exclusion criteria, and complete baseline (Day 0) will be considered enrolled in this study.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Adults who were prescribed and had one successful fill for zuranolone within 12 months following end of pregnancy for the treatment of PPD from March 2026 to July 2026 through CVS Specialty Pharmacy. * Currently reside in the United States. * Able to complete the questionnaires independently. Key Exclusion Criteria: * Prior fill of zuranolone or brexanolone in last 12 months. * Participants with 2 or more doses of zuranolone at the time of screening. * Current or history of bipolar disorder. * Failure to complete baseline surveys prior to 2nd dose of zuranolone. * Pregnancy that ended more than 12 months ago. Other protocol-defined Inclusion/Exclusion criteria may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Depression, postpartum are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CVS Health
Woonsocket, Rhode Island, 02895, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can flickering light and pulsed sound shield new mothers from postpartum depression?
- Can group prenatal care with social support reduce preterm births?
- Robot-Guided brain zaps: a new hope for postpartum depression?
- Could epidurals shield new mothers from postnatal depression?
- Yoga before birth may ease postpartum blues, study finds
- Can pediatrician training improve Parent-Child bonds?